Both Urovant Sciences Ltd. (NASDAQ:UROV) and Myovant Sciences Ltd. (NYSE:MYOV) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urovant Sciences Ltd.	N/A	0.00	101.47M	-3.21	0.00
Myovant Sciences Ltd.	N/A	0.00	246.79M	-3.80	0.00

Table 1 demonstrates Urovant Sciences Ltd. and Myovant Sciences Ltd.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Urovant Sciences Ltd. (NASDAQ:UROV) and Myovant Sciences Ltd. (NYSE:MYOV)’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Urovant Sciences Ltd.	0.00%	0%	0%
Myovant Sciences Ltd.	0.00%	-451.3%	-153.5%

Liquidity

Urovant Sciences Ltd.’s Current Ratio and Quick Ratio are 11 and 11 respectively. The Current Ratio and Quick Ratio of its competitor Myovant Sciences Ltd. are 3.5 and 3.5 respectively. Urovant Sciences Ltd. therefore has a better chance of paying off short and long-term obligations compared to Myovant Sciences Ltd.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Urovant Sciences Ltd. and Myovant Sciences Ltd.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Urovant Sciences Ltd.	0	0	2	3.00
Myovant Sciences Ltd.	0	0	0	0.00

Urovant Sciences Ltd.’s upside potential currently stands at 197.14% and an $26 consensus target price.

Institutional and Insider Ownership

Urovant Sciences Ltd. and Myovant Sciences Ltd. has shares held by institutional investors as follows: 22.8% and 30.3%. Insiders held roughly 74.9% of Urovant Sciences Ltd.’s shares. Comparatively, Myovant Sciences Ltd. has 0.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Urovant Sciences Ltd.	7.69%	46.7%	59.01%	0%	0%	95.45%
Myovant Sciences Ltd.	6.05%	24.62%	20.95%	1.37%	57.94%	40.04%

For the past year Urovant Sciences Ltd.’s stock price has bigger growth than Myovant Sciences Ltd.

Summary

Urovant Sciences Ltd. beats on 7 of the 7 factors Myovant Sciences Ltd.

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.